

Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer and Breast Cancer

April 3-4, 2015, Houston, TX

Houston Marriott at the Texas Medical Center 6580 Fannin Street, Houston, TX 77030

Program Directors: John V. Heymach, MD, PhD, Houston, TX • Mark Pegram, MD, Stanford, CA

Educational Grants This activity is supported by education grants from:
Lilly USA, LLC; Novartis Pharmaceuticals; Boehringer-Ingelheim; Genomic Health

Physician Continuing Education

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-providership of A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

The A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.


Nursing Continuing Education

Accreditation Statement:

Accreditation Statement: American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for: Day 1-April 3, 2015, 6.5 Contact Hours; Day 2-April 4, 2015, 6.5 Contact Hours. Please check with licensing board to verify credits can be claimed in your state.

Pharmacist Continuing Education

Accreditation Statement:

 American Health Resource is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation:

Day 1: April 3, 2015, (NSCLC) ACPE UAN: 0280-9999-15-003-L01-P, 6.5 Contact Hours (0.65 CEUs)

Day 2: April 4, 2015, (Breast Cancer) ACPE UAN: 280-9999-15-004-L01-P, 6.5 Contact Hours (0.65 CEUs)

Participant Requirements for Credit:

- Participants must fully attend all sessions as well as pass in a completed signature verification form (No partial credit will be given).
- Participants can earn Continuing Education credits for this program by electronically logging onto the website <https://ce.ahrevents.com/> and completing the session evaluation form for sessions attended.
 - o **Nurses:** After completion of the evaluation, certificate of credit can be printed.
 - o **Pharmacists:** After completion of the activity evaluation, pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.

***Only Certificates of Credit issued from CPE Monitor are valid in the US**
***CPE Monitor will not accept credits after 60 days from the session date**

- All participant names will be checked against program attendance sheets for verification of attendance.

Disclosure & Evaluation:

All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.

Participants may reserve guest rooms by calling (713) 796-0080

Jointly sponsored by



For online registration and more information visit: www.cancernetus.com

REGISTRATION FORM

Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer and Breast Cancer

First Name _____ Middle Initial _____ Last Name _____
 Physician Pa-C NP PhD Pharmacist Industry Nurse Other
 Mailing Address _____

City _____ State _____ Zip Code _____
 Phone _____ Fax _____
 E-Mail _____
 Speciality _____

Registration Fee (Registration fee partially covers buffet breakfast, lunch and syllabus book)

	Early Registration Fee - Up to 3/9/15		Discounted Registration Fee - 3/10/15-3/27/15		Regular Registration Fee - 3/28/15 -4/4/15	
	1 Day	2 Day	1 Day	2 Day	1 Day	2 Day
<input type="checkbox"/> Registration for Lung (April 3rd) only.	\$95.00	\$150.00	\$115.00	\$170.00	\$135.00	\$190.00
<input type="checkbox"/> Registration for Breast (April 4th) only.	\$60.00	\$90.00	\$70.00	\$105.00	\$85.00	\$120.00
<input type="checkbox"/> Registration for both Lung & Breast (April 3-4)	\$60.00	\$90.00	\$70.00	\$105.00	\$85.00	\$120.00
<input type="checkbox"/> Physicians	\$250.00	\$300.00	\$300.00	\$350.00	\$350.00	\$400.00
<input type="checkbox"/> Nurses, Nurse Practitioners, Physician Assistants						
<input type="checkbox"/> Pharmacists, Fellows						
<input type="checkbox"/> Industry †						

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

No Refund. Substitution is allowed

Payment may be made: MC Visa Discover Check

Credit Card Number _____ Expiration Date _____

Name and address (as given on the monthly credit card statement) _____

Pharmacists only: NABP e-profile # _____ Birth Date (MMDD): _____

Signature _____

Register online at www.cancernetus.com

Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, if any, please call 972-459-5222 or E-mail: brianw@cancernetus.com

If you wish to be removed from this fax list, please call 1-866-205-9658 ext. 42870.

Fax registration to:
443-267-0016

Mail registration to:
860 Hebron Pkwy, Suite 1104
Lewisville, TX 75057

Check box to receive information about Live and Webcast programs. You can unsubscribe at any time.

Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer and Breast Cancer

April 3-4, 2015, Houston, TX

Learning Objectives - Lung Cancer - April 3, 2015

After completing this activity, the participant should be better able to:

- Outline the role of staging and histology in the treatment of lung cancer
- Select lung cancer patients for personalized chemotherapy based on molecular profiling
- Identify the role of personalized maintenance therapy in lung cancer
- Summarize the important cooperative group clinical trials for lung cancer
- Outline the clinical data supporting the optimal use of EGFR and ALK inhibitors for lung cancer
- Identify and utilize radiation therapy options for lung cancer
- Identify the role of immune checkpoint pathway inhibitors for lung cancer
- Update the role of KRAS and PARP inhibitors in the treatment of lung cancer
- Evaluate the adjuvant therapy options for lung cancer
- Discuss economic value of novel treatments for lung and breast cancer

Learning Objectives - Breast Cancer - April 4, 2015

After completing this activity, the participant should be better able to:

- Review treatment options for early breast cancer
- Outline treatment options for HER-2 positive advanced/metastatic breast cancer
- Indicate the utility of genomic analysis in identifying subtypes and novel targets for triple negative breast cancer
- Identify emerging chemotherapeutic and endocrine agents in treatment of breast cancer
- Describe strategies to treat bone loss in women with breast cancer
- Review genetic counseling and management of breast cancer in BRCA carriers
- Indicate the optimal use of m-TOR inhibitors in the treatment of endocrine-sensitive metastatic breast cancer
- Identify the role of predictive and prognostic markers for response and survival in patients with breast cancer
- Identify the use of prognostication tools such as EndoPredict Score and Oncotype DX RS for breast cancer
- Describe the current status of radiation therapy in optimizing local control in breast cancer

Agenda Topics (Tentative)

LUNG CANCER - FRIDAY - April 3, 2015

Primacy of Staging and Histology in the Treatment of NSCLC
TBD

Molecular Profiling in the Treatment of NSCLC
John V. Heymach, MD, PhD

EGFR and ALK Inhibitors for NSCLC
George Blumenschein, MD

Current ECOG, CALGB and SWOG Clinical Trials
Vassiliki Papadimitrakopoulou, MD

Update on Radiation Therapy Options for Lung Cancer
Hak Choy, MD

Maintenance Therapy for NSCLC: Is this Now Standard?
David Gerber, MD

KRAS and PARP Inhibitors for NSCLC
John V. Heymach, MD, PhD

Adjuvant Therapy for NSCLC: Consensus and Controversies
TBD

Harnessing Immune System for the Treatment of NSCLC
TBD

Defining the Economic Value of New NSCLC & Breast Cancer Therapies - *Jim Koeller, MA*

BREAST CANCER - SATURDAY - April 4, 2015

State of the Art: Breast Cancer Therapy 2014
Vicente Valero, MD

Advances in the treatment options for patients with HER2-positive metastatic breast cancer - *Mark Pegram, MD*

Optimizing Adjuvant Hormonal Therapy in Breast Cancer: Current Status - *Mark Pegram, MD*

Comprehensive Genomic Analysis: Identification of Subtypes and Novel Targets for Triple-negative Breast Cancer
Stacy Moulder, MD

Role of mTOR Inhibitors in the Treatment of Endocrine-sensitive Metastatic Breast Cancer - *Mariana Chavez-MacGregor, MD*

Therapeutic Strategies Directed at Prevention and Management of Bone Metastasis in Women with Breast Cancer
Naoto Ueno, MD

Genetic Counseling and Management of Breast Cancer in BRCA Carriers: Role of New Approaches in Testing
Mariana Chavez-MacGregor, MD

Predictive and Prognostic Markers for Response and Survival in Breast Cancer - *TBD*

Treatment Insights Based on Molecular Subtypes and Novel Diagnostics: Endopredict vs Oncotype RS - *TBD*

New Insights into Optimizing Local-regional Control in Breast Cancer: Personalizing Therapy - *Eric A. Strom, MD*